Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.
Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-degrading enzyme which suppresses T lymphocyte activity. IDO activity can be determined by relating kynurenine, the main metabolite of tryptophan, to tryptophan (kyn/trp). We have demonstrated recently that systemic lupus erythematosus (SLE) is activated during the sunny season as measured by the European Consensus Lupus Activity Measurement Index (ECLAM) activity score. Our aim here was to establish whether IDO-dependent mechanisms are involved in the activation process of SLE. Kyn/trp was measured by reverse-phase high-performance liquid chromatography (HPLC) in 33 (30 female, three male) SLE patients in winter, spring and summer and in 309 healthy control subjects. At the same time-points the SLE patients were examined by a rheumatologist and a dermatologist and the activity of SLE assessed by the ECLAM score. IDO activity was higher in SLE patients than in healthy subjects. There was no seasonal variation in IDO activity in SLE patients and it did not correlate with the ECLAM activity score in winter. However, there was a significant correlation between IDO activity and the ECLAM score both in spring and in summer. High IDO activity in winter predicted subsequent activation of SLE in spring and summer. Our results indicate that IDO-dependent immunosuppressive mechanisms are activated in SLE patients. Exposure to sunlight or another factor causing seasonal variation in SLE activity leads to insufficiency of this suppression in a subgroup of patients, causing activation of SLE. High IDO activity in winter predicts activation of SLE in the sunny season.
Pertovaara
M
M
Department of Internal Medicine, Section of Rheumatology, Tampere University Hospital, Tampere, Finland. marja.pertovaara@uta.fi
Hasan
T
T
Raitala
A
A
Oja
S S
SS
Yli-Kerttula
U
U
Korpela
M
M
Hurme
M
M
D000328:Adult; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000097:blood*; D007737:Kynurenine / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000201:enzymology* / Q000209:etiology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012621:Seasons; D012720:Severity of Illness Index; D013472:Sunlight / Q000009:adverse effects*; D014364:Tryptophan / Q000097:blood
D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D007737:Kynurenine; D014364:Tryptophan
Immunobiology. 2000 Apr;201(5):621-30
10834318
Curr Opin Immunol. 2006 Apr;18(2):220-5
16460921
J Immunol. 2003 Jun 15;170(12):5809-13
12794104
Nat Rev Immunol. 2004 Oct;4(10):762-74
15459668
Ann Rheum Dis. 2004 Nov;63(11):1498-500
15479902
Arthritis Rheum. 1982 Nov;25(11):1271-7
7138600
Clin Exp Rheumatol. 1985 Oct-Dec;3(4):303-10
3878760
Ann Rheum Dis. 1989 Jun;48(6):461-3
2742401
Clin Exp Rheumatol. 1992 Sep-Oct;10(5):541-7
1458710
Br J Rheumatol. 1997 Apr;36(4):449-52
9159538
Scand J Rheumatol. 1997;26(6):435-9
9433403
Lupus. 1999;8(4):269-73
10413204
Immunol Today. 1999 Oct;20(10):469-73
10500295
Clin Exp Immunol. 2005 Oct;142(1):155-61
16178870
Mol Immunol. 2006 Mar;43(7):1054-6
15992929
Clin Chim Acta. 2006 Feb;364(1-2):82-90
16139256
Clin Chem. 2002 Mar;48(3):579-81
11861457